TAIPEI, Taiwan – Medigen Biotechnology Corp. said following a meeting Sunday with an independent committee to discuss results midway through the multinational phase III trial for PI-88, the company's adjuvant treatment of hepatocellular carcinoma after surgical resection, preliminary results showed no improvement of survival rates over placebo. The company's stock price has been hit hard in response, as have many other companies in Taiwan's drug development sector.
TAIPEI, Taiwan – Medigen Biotechnology Corp. said following a meeting Sunday with an independent committee to discuss results midway through the multinational phase III trial for PI-88, the company's adjuvant treatment of hepatocellular carcinoma after surgical resection, preliminary results showed no improvement of survival rates over placebo.
TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.
TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.
TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.
TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.
TAIPEI, TAIWAN – Neurovive Pharmaceutical AB’s Hong Kong-registered subsidiary, Neurovive Pharmaceutical Asia Ltd., has signed a financial services agreement with Yuanta Securities Co. Ltd. for the Taiwanese company to be its underwriter in a planned initial public offering (IPO) in Taiwan.
TAIPEI, Taiwan – For Western biopharmaceutical executives seeking an entry point into Asia, Taiwan may be a good gateway. And for Taiwanese innovators in need of outside partners to back still under-the-radar drug candidates: be more aggressive. Those were a few of the messages heard at the second annual Biologics World Taiwan conference here.
TAIPEI, Taiwan – With Singapore-headquartered Aslan Pharmaceuticals Pte. Ltd. last week announcing that it had opened a new office here, the company has moved that much closer toward its goal of taking advantage of clinical trial infrastructure in Asia to develop novel medicines for global markets.
TAIPEI, Taiwan – Taiwan Liposome Co. Ltd. (TLC), of Taipei, recently signed a distribution agreement giving Sandoz AG, the generics drug affiliate of Novartis AG, of Basel, Switzerland, distribution rights in the European Union (EU) and U.S. for TLC’s generic version of Gilead Sciences Inc.’s Ambisome, a liposomal rendering of antifungal drug amphotericin B.
